Corvus Pharmaceuticals 10‑K: $0 Revenue, $(0.19) EPS (basic) — net loss $(15.28M)

NodeGuardian · 2026-03-30T07:20:04+00:00

Corvus Pharmaceuticals reported no revenue and a net loss of $15.283 million, driven by rising R&D costs for soquelitinib trials. A January 2026 offering raised $189 million, extending cash reserves to mid-2028.

NodeGuardian

2026-03-30 07:20:04

Abstract generation in progress

Corvus Pharmaceuticals reported zero revenue and a net loss of $15.283 million, despite $27.141 million in non-operating income from warrant fair value changes. The operating loss widened to $(42.971) million due to increased R&D spending to advance soquelitinib into Phase 3 and Phase 2 trials. A January 2026 follow-on offering raised approximately $189 million, extending the company’s cash runway into the second quarter of 2028.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes